LEADER 04086nam 2201009z- 450 001 9910557507203321 005 20231214133239.0 035 $a(CKB)5400000000044484 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76719 035 $a(EXLCZ)995400000000044484 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNew Perspective in Atrial Fibrillation 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (224 p.) 311 $a3-0365-1822-3 311 $a3-0365-1821-5 330 $aIn spite of the large volume of associated research, the pathophysiological mechanisms involved in atrial fibrillation (AF) onset and recurrence remain uncertain. This may explain why the performances of thromboembolic and bleeding prediction scores in AF patients are limited. In the past few years, the concept of atrial cardiopathy has emerged as a promising lead to connect AF to stroke, heart failure, and inflammatory processes: indeed, all of the mechanisms associated with atrial remodeling and the development of atrial cardiopathy are also likely to promote the development of AF. This recent concept of atrial cardiopathy suggests that the real trigger of stroke may be an abnormal atrial substrate rather than atrial rhythm itself. In this setting, AF could be seen as a symptom of atrial cardiopathy rather than a risk factor of stroke. In the absence of validated clinical markers of atrial cardiopathy, the search for the mechanism of AF remains the cornerstone of cardioembolic stroke prevention for now.The aim of this Special Issue is to gather basic research as well as pathophysiological and epidemiological papers focused on the relationship between atrial substrates and atrial fibrillation onset, recurrence, and outcomes. 606 $aMedicine$2bicssc 610 $apostoperative atrial fibrillation 610 $abiomarkers 610 $acoronary artery bypass grafting 610 $amiRNA 610 $acircRNA 610 $amtDNA 610 $aSNPs 610 $aatrial fibrillation 610 $aacute myocardial infarction 610 $aheart rate variability 610 $aautonomic nervous system 610 $ableeding risk 610 $aage 610 $aleft atrial appendage closure 610 $acoronary artery disease 610 $aprognosis 610 $aanticoagulation 610 $aantiplatelet therapy 610 $ahypertension 610 $aelderly 610 $aprevention 610 $aganglionated plexi 610 $aablation 610 $adementia 610 $aearly-onset 610 $aischemic stroke 610 $arisk factor 610 $anew oral anticoagulants 610 $amitochondria 610 $acardiac remodeling 610 $apharmacotherapy 610 $aelectroporation 610 $apulsed field ablation 610 $acardiac 610 $aheart 610 $aarrhythmia 610 $aNOAC 610 $aVKA 610 $astatin 610 $aoutcome 610 $amortality 610 $aparoxysmal atrial fibrillation 610 $acatheter ablation 610 $aepicardial adipose tissue 610 $apersistent atrial fibrillation 610 $aposterior wall 610 $ahybrid ablation 610 $aconvergent ablation 610 $aatrial tachycardia 610 $amechanism 610 $aspatiotemporal dispersion 610 $aleft atrial appendage occlusion 610 $aBNP 610 $aatrial remodeling 610 $aatrial cardiopathy 610 $acardiac ablation 610 $airreversible electroporation 615 7$aMedicine 700 $aGuenancia$b Charles$4edt$01290021 702 $aGuenancia$b Charles$4oth 906 $aBOOK 912 $a9910557507203321 996 $aNew Perspective in Atrial Fibrillation$93021308 997 $aUNINA